Patients who undergo transplant face an increased risk of skin cancer because of their immunosuppressed status, explained Christine Ko, MD, professor of dermatology and pathology at Yale University.
Patients who undergo transplant face an increased risk of skin cancer because of their immunosuppressed status, notably from the medicines they are on to prevent organ rejection, some of which can cause DNA mutations, explained Christine Ko, MD, professor of dermatology and pathology at Yale University.
Transcript
What factors predispose transplant patients to a higher risk of skin cancers?
So I enjoy transplant dermatology because I've been interested for a long time in skin cancer. One of the more common skin cancers they get is reported to be squamous cell carcinoma, which has been a long-standing interest of mine, initially more from the dermatopathology side. So these types of patients, some people are surprised. Some of my friends are like, “Why are you seeing transplant patients?” I reply, “Well, I just look at their skin.” The reason they're at increased risk for skin cancer is because of the immunosuppressive medicines they're on to prevent rejection of the transplanted organ. The great thing is, medicine is continuing to evolve and some of the newer immunosuppressive medicines that they're put on are not as promoting of skin cancer.
So that's great, but for example, azathioprine used to be used more, and that can directly cause mutations in our genetic code, in our DNA. And that's not good. There's a relationship also with sun exposure and sun damage; sun also being able to cause ultraviolet light–induced mutations. And so anything that can sort of add on to that is not good, and azathioprine can do that.
Cyclosporine and tacrolimus are other medicines that are used more often now, compared to azathioprine, and they're both in a class called calcineurin inhibitors. Those medicines don't directly cause DNA damage—like kind of inserting themselves into the DNA the way that azathioprine does—so that's good. But both of those also have strong immunosuppressive effects, which transplant doctors want for the sake and the patient wants too for the sake of their transplanted organ, but [they] can reduce immune surveillance, which is important for preventing skin cancer, particularly in sun-damaged skin of these patients who sometimes have very light skin and a significant amount of sun exposure from the past.
Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS
June 24th 2025In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.
Read More
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
Many Patients Stop GLP-1s Before Reaching Target Dose: Hamlet Gasoyan, PhD
June 19th 2025Discontinuing the weight loss treatment before hitting the recommended maintenance dose contributes to low-value care despite provider follow-up and efforts to manage side effects, says Hamlet Gasoyan, PhD, Cleveland Clinic.
Read More